Chord Energy Corporation CHRD 深 沪
等待开盘 04-02 09:30:00 美东时间
136.96
-5.220
-3.67%
华盛通- 最 高141.00
- 今 开137.65
- 成交量 112.15万股
- 最 低 134.6801
- 昨 收 142.18
- 总市值 77.64亿
- 52周最高 148.415
- 市盈率 静 185.46
- 换手率 1.98%
- 52周最低 81.46
- 委 比 2.72%
- 总股本 5668.61万
- 历史最高 176.83
- 量 比 1.09
- 振 幅 4.44%
- 历史最低 -61.035
- 每 手 1
- 风险率 11.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Citigroup Maintains Neutral on Chord Energy, Raises Price Target to $155
Citigroup analyst Paul Diamond maintains Chord Energy (NASDAQ:CHRD) with a Neutral and raises the price target from $120 to $155.
04-01 02:57
美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Truist Securities Initiates Coverage On Chord Energy with Buy Rating, Announces Price Target of $169
Truist Securities analyst Gabe Daoud initiates coverage on Chord Energy (NASDAQ:CHRD) with a Buy rating and announces Price Target of $169.
03-24 22:22
Chord Energy Corporation Announces Annual Shareholder Meeting
Chord Energy Corporation Announces Annual Shareholder Meeting Chord Energy will hold its annual meeting in Houston, Texas on April 29, 2026. Shareholders will vote on the election of 11 directors to serve until the 2027 annual meeting. An advisory vote on executive compensation will also be put to s
03-19 21:24
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monday
03-16 18:00
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
Piper Sandler Maintains Overweight on Chord Energy, Raises Price Target to $190
Piper Sandler analyst Mark Lear maintains Chord Energy (NASDAQ:CHRD) with a Overweight and raises the price target from $158 to $190.
03-13 00:00
